UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 21 von 25
Datensatz exportieren als...
BibTeX
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
Movement disorders, 2010-09, Vol.25 (12), p.1801-1808
Schwid, Steven R.
Bausch, Janice
Oakes, David
Schuchter, Lynn
Tanner, Caroline
Forrest, Misser
Lang, Anthony E.
Shoulson, Ira
2010
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Schwid, Steven R.
Bausch, Janice
Oakes, David
Schuchter, Lynn
Tanner, Caroline
Forrest, Misser
Lang, Anthony E.
Shoulson, Ira
Titel
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
Ist Teil von
Movement disorders, 2010-09, Vol.25 (12), p.1801-1808
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2010
Quelle
MEDLINE
Beschreibungen/Notizen
We performed a placebo‐controlled trial of CEP‐1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long‐term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in a large cohort of PD patients followed prospectively including periods before and after patients developed disability requiring dopaminergic therapy. This was a multicenter study of 806 patients with early PD, without disability requiring dopaminergic therapy, assigned randomly to placebo or one of three doses of CEP‐1347. Patients were monitored for an average of 1.8 years (1,467 patient‐years) with routine cancer screening evaluations and annual skin examinations by a dermatologist. There was no significant excess of cancers among patients taking CEP‐1347 compared with placebo for any cancer type (all P > 0.1). Nonmelanoma skin cancers were the most common cancer type observed. The incidence of melanomas was 20.9 times that predicted in the general population. Most melanomas occurred in patients who had never taken dopaminergic therapy. We found no evidence that CEP‐1347 affected cancer incidence within 2 years of follow‐up. Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted. © 2010 Movement Disorder Society
Sprache
Englisch
Identifikatoren
ISSN: 0885-3185
eISSN: 1531-8257
DOI: 10.1002/mds.23006
Titel-ID: cdi_proquest_miscellaneous_755192639
Format
–
Schlagworte
Aged
,
apoptosis
,
Biological and medical sciences
,
cancer
,
Carbazoles - adverse effects
,
Carbazoles - therapeutic use
,
Chi-Square Distribution
,
Comorbidity
,
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
,
Disease Progression
,
Double-Blind Method
,
Follow-Up Studies
,
Humans
,
Incidence
,
L-dopa
,
Longitudinal Studies
,
Medical sciences
,
Melanoma
,
Middle Aged
,
Neoplasms - epidemiology
,
Neoplasms - etiology
,
Neurology
,
Parkinson Disease - drug therapy
,
Parkinson Disease - epidemiology
,
Parkinson's disease
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX